Komori
Earnings4893Noile-Immune Biotech Inc.Pharmaceuticals

Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 (Japanese GAAP, Non-Consolidated)

No business revenue was recorded for the six-month interim period of the fiscal year ending December 2026, and the operating loss widened from the same period of the previous year. Meanwhile, the ordinary loss and interim net loss narrowed from the same period of the previous year.

Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-7457
¥ thousand
Wording
Avoiding a definitive answer
How definitive the wording is.

Results for this period

Interim period (second quarter)1 January 2026–30 June 2026Non-consolidated (standalone)Japanese GAAP
Operating profit-419¥ million
Ordinary income-370¥ million
Net income attributable to owners of the parent-372¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Net income per share△¥8.59
Financial position at period-end
Total assets3,664¥ million
of which net assets 3,574 ¥ millionEquity ratio 97.3%vs. prior year-end -0.5pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating-373,490
Investment+132
Net change-373,358

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥3,544,964 thousand
Segment revenueOmitted because the Company has a single segment
Segment profitOmitted because the Company has a single segment
Outlook and shareholder returns
Annual Dividend Forecast¥0 → ¥0(0.0%)
Factors Behind Changes in Business Performance

Although no business revenue was recorded, continued development activities resulted in an operating loss of ¥419,977 thousand.

Disclosure regarding the going concern assumption

No applicable matters

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End43,399,118 Shares
Treasury Shares at Period-End125 Shares
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 January 2026–30 June 2026
Operating profit¥-419 million
Ordinary income¥-370 million
Profit attributable to owners of the parent¥-372 million
Net income per share△¥8.59
Equity ratioEnd of the current fiscal period 97.3 / End of previous period 97.8
Total assets¥3,664 million
Net assets¥3,574 million
Cash flows from operating activities¥-373,490 thousand
Cash flows from investing activities¥132 thousand
Cash and cash equivalents at end of period¥3,544,964 thousand
Annual Dividend Forecast¥0 → ¥0(0.0%)
Segment revenueOmitted because the Company has a single segment
Segment profitOmitted because the Company has a single segment
Disclosure regarding the going concern assumptionNo applicable matters
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End43,399,118 Shares
Treasury Shares at Period-End125 Shares
Factors Behind Changes in Business PerformanceAlthough no business revenue was recorded, continued development activities resulted in an operating loss of ¥419,977 thousand.
Items this document does not state (14)
Net SalesOperating MarginCash flows from financing activitiesFull-year earnings forecastRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidationMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No business revenue was recorded, and continued development activities resulted in an operating loss.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 (Japanese GAAP, Non-Consolidated) | Noile-Immune Biotech Inc. (4893) timely disclosure | Komori